.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Healthtrust
Citi
AstraZeneca
Colorcon
McKesson
Novartis
Deloitte
Daiichi Sankyo
Moodys

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,426,586

« Back to Dashboard

Which drugs does patent 8,426,586 protect, and when does it expire?


Patent 8,426,586 protects GILOTRIF and is included in one NDA. There has been one Paragraph IV challenge on Gilotrif.

This patent has fifty-eight patent family members in thirty-three countries.

Summary for Patent: 8,426,586

Title:Process for preparing amino crotonyl compounds
Abstract: An improved process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline and related aminocrotonyl compounds and the preparation of a suitable salt of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline for use as a pharmaceutically active substance.
Inventor(s): Soyka; Rainer (Biberach, DE), Rall; Werner (Mittelbiberach, DE), Schnaubelt; Juergen (Oberhoefen/Warthausen, DE), Sieger; Peter (Mittelbiberach, DE), Kulinna; Christian (Attenweiler, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:11/457,622
Patent Claim Types:
see list of patent claims
Compound; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer IngelheimGILOTRIFafatinib dimaleateTABLET;ORAL201292-001Jul 12, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
Boehringer IngelheimGILOTRIFafatinib dimaleateTABLET;ORAL201292-002Jul 12, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
Boehringer IngelheimGILOTRIFafatinib dimaleateTABLET;ORAL201292-003Jul 12, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,426,586

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 49 113Oct 17, 2003

International Patent Family for Patent: 8,426,586

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Serbia20130524► Subscribe
Portugal1678165► Subscribe
Portugal2508521► Subscribe
Serbia53398► Subscribe
Serbia20060260► Subscribe
Peru09652005► Subscribe
New Zealand583049► Subscribe
Peru02672010► Subscribe
New Zealand547154► Subscribe
Norway335103► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Daiichi Sankyo
Cantor Fitzgerald
US Army
Fuji
QuintilesIMS
Express Scripts
Chubb
Cipla
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot